Drug intelligence / Profile preview

miR-663a

Development stage
Preclinical
Lead developer
The Ohio State University
Modality
RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous
01

Overview

miR-663a is a microRNA that functions as a tumor suppressor, particularly in the context of pancreatic ductal adenocarcinoma (PDAC). It is frequently epigenetically silenced in PDAC tissues and cell lines. Restoration of miR-663a expression—either through synthetic mimics or via epigenetic reactivation using agents like 3-deazaneplanocin-A (DZNep)—has been shown to inhibit tumor progression. miR-663a acts by directly targeting the 3' untranslated region (UTR) of Transforming Growth Factor Beta 1 (TGF-β1) mRNA, leading to its degradation or translational inhibition. This suppression of the TGF-β1 signaling pathway attenuates the epithelial-to-mesenchymal transition (EMT), a key process in cancer metastasis and chemoresistance. Preclinical studies in orthotopic mouse models have demonstrated that miR-663a overexpression significantly reduces tumor burden and metastatic spread to the liver, lungs, and spleen.

Other names
microRNA-663amicroRNA663amicroRNA 663a
02

Targets

GNG7 (G protein subunit gamma 7)IGF2 (Insulin-like growth factor 2)JUNB (Transcription factor JunB mRNA)FOS (Activator Protein 1)SPTBN4 (Spectrin beta chain, non-erythrocytic 4)TNNTGFB1 (Transforming growth factor Beta-1 proprotein)

Beyond the preview

Go deeper on miR-663a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-663a.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call